Share|

Participation on February 27, 2014 (pursuant to Article 6 of the law of May 2, 2007 on the disclosure of large shareholdings).


BRUSSELS (Belgium), March 6, 2014 - 18:30 (CET) - regulated information

Pursuant to Article 14 of the law of May 2, 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification from Vanguard Health Care Fund (c/o The Vanguard Group, 455 Devon Park Drive, Wayne, PA 19087 USA).

Vanguard Health Care Fund has notified that, following the recent capital increase of UCB NV/SA of February 27, 2014 (see the press release of the same date for more information), it fell below the 5%-threshold.

On February 27, 2014, Vanguard Health Care Fund owned 9,345,949 UCB shares with voting rights, representing 4,96% of the total number of UCB voting rights (188,541,209).

Holders of voting rights

Notification of June 11, 2013

Notification of March 3, 2014

# of voting rights

# of voting rights

% of voting rights

Vanguard Health Care Fund

9,345,949

9,345,949

4.96 %

TOTAL

9,345,949

9,345,949

4.96%

An updated overview of the UCB SA/NV large shareholdings is included in the corporate governance charter of UCB SA/NV, which will be published on UCB SA/NV's website.

For further information

  • Antje Witte, Investor Relations UCB

T +32.2.559.9414, antje.witte@ucb.com

  • Alexandra Deschner, Investor Relations, UCB

T +32 2 559 9683, alexandra.deschner@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 8700 people in approximately 40 countries, the company generated revenue of € 3.4 billion in 2013. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

Forward looking statements

distributed by